福里斯特 FOR 深 滬
已收盤 02-06 16:00:00 美东时间
29.27
+0.200
+0.69%
華盛通- 最 高29.845
- 今 開29.15
- 成交量 18.53万股
- 最 低 28.8601
- 昨 收 29.07
- 總市值 14.90亿
- 52周最高 29.845
- 市盈率 靜 8.90
- 換手率 0.36%
- 52周最低 18.00
- 委 比 -30.72%
- 總股本 5089.21万
- 歷史最高 40.92
- 量 比 0.72
- 振 幅 3.39%
- 歷史最低 7.95
- 每 手 1
- 風險率 2.90%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 希捷科技、德州仪器、HCA控股、通用汽车、波音、UPS等或多家机构上调目标价；布朗保险、康沃系统、Qorvo、联合健康等遭多家机构下调目标价
今日重点评级关注：Piper Sandler：维持Praxis Precision Medicine"超配"评级，目标价从450美元升至1200美元；Tigress Financial：维持Main International ETF"买入"评级，目标价从52美元升至66美元
01-29 11:06
Citigroup Maintains Buy on Forestar Group, Raises Price Target to $38
Citigroup analyst Anthony Pettinari maintains Forestar Group (NYSE:FOR) with a Buy and raises the price target from $36 to $38.
01-28 20:31
Forestar Earnings Call: Growth Intact, Margins Under Strain
Forestar (($FOR)) has held its Q1 earnings call. Read on for the main highlight...
01-21 08:06
Forestar Group Affirms FY2026 Sales Guidance of $1.600B-$1.700B
Forestar Group (NYSE:FOR) affirms FY2026 sales outlook from $1.600 billion-$1.700 billion to $1.600 billion-$1.700 billion.
01-20 20:01
Forestar Group Q1 EPS $0.30 Misses $0.36 Estimate, Sales $273.000M Beat $260.966M Estimate
Forestar Group (NYSE:FOR) reported quarterly earnings of $0.30 per share which missed the analyst consensus estimate of $0.36 by 17.36 percent. This is a 6.25 percent decrease over earnings of $0.32 per share from the
01-20 19:32
Earnings Scheduled For January 20, 2026
Companies Reporting Before The Bell • Peoples Bancorp (NASDAQ:PEBO) is projecte...
01-20 19:11
Forestar Group Q1 2026 Earnings Preview
Forestar Group (FOR) is scheduled to announce Q1 earnings results on Tuesday, January 20th, before market open. The consensus EPS Estimate is $0.30 (-6.3% Y/Y) and the consensus Revenue Estimate is $2...
01-20 00:22
美股大行评级 | 最高255美元！9家大行集体上调Palantir目标价；Axsome、Exact、Fabrinet、ZoomInfo、爱德士、MongoDB、安森美半导体等也获多家大行上调目标价
今日重点评级关注：瑞银：维持Syndax Pharmaceuticals"买入"评级，目标价从35美元升至38美元；HC Wainwright & Co.：维持Benitec Biopharma"买入"评级，目标价从28美元升至35美元
2025-11-05 10:35
美股大行评级 | 最高350美元！16家大行上调谷歌目标价！Meta遭12家大行下调目标价；潜在涨幅1456.29%！NRX Pharmaceuticals获Ascendiant Capital升目标价至47美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持NRX Pharmaceuticals"买入"评级，目标价从46美元升至47美元；富国银行：维持Kyverna Therapeutics"超配"评级，目标价从27美元升至31美元
2025-10-31 10:25
